Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals (SUPN) is a leading biopharmaceutical innovator focused on developing advanced treatments for central nervous system disorders. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's clinical developments, regulatory milestones, and strategic initiatives in neurology and psychiatry.
Access comprehensive coverage of SUPN's progress in treating epilepsy, ADHD, and movement disorders through reformulated therapeutics. Our curated news feed includes updates on FDA submissions, partnership announcements, clinical trial results, and market expansion efforts – all essential for understanding the company's position in CNS therapeutics.
Key areas of focus include non-stimulant ADHD treatments, extended-release neurology medications, and novel approaches to Parkinson's-related conditions. Stay informed about SUPN's pipeline advancements and commercial strategies through verified press releases and objective analysis.
Bookmark this page for direct access to Supernus Pharmaceuticals' latest developments in neuroscience innovation. Check regularly for updates on product approvals, research collaborations, and financial performance indicators relevant to CNS treatment advancements.
Supernus Pharmaceuticals reported 2022 total revenues of $667.2 million, a 15% increase from 2021. The fourth quarter saw Qelbree® net sales of $23.6 million, up 29% from Q3, while GOCOVRI® sales reached $29.2 million, a 13% increase year-over-year. Total net product sales for the full year were $649.4 million, a 14% increase. The company anticipates 30% growth in 2023 revenues, excluding Trokendi XR® sales which face generic competition. Net earnings for Q4 stood at $25.5 million, with an EPS of $0.43.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced a new credit line agreement with UBS Bank USA, granting access to an uncommitted demand secured line of credit up to $150 million. The credit line can be drawn at any time, allowing the company to enhance its financial flexibility. Borrowing rates are determined based on either a fixed or variable interest rate linked to UBS’s funding rates. CEO Jack Khattar expressed confidence in this move to strengthen the company's balance sheet.
Supernus Pharmaceuticals (Nasdaq: SUPN) will report its Q4 and full year 2022 financial results on February 28, 2023, after market close. The conference call with CEO Jack Khattar and CFO Tim Dec is scheduled for 4:30 p.m. ET on the same day, followed by a Q&A session. A live webcast will be available on the company’s Investor Relations website. Supernus focuses on developing treatments for central nervous system diseases and has a diverse portfolio that includes approved therapies for various conditions such as epilepsy and Parkinson's disease.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that its President and CEO, Jack Khattar, will participate in a fireside chat and host investor meetings at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 10:30 a.m. ET. The event will take place in New York City from November 29 to December 1, 2022. Investors can schedule meetings through the conference coordinator and access a live audio webcast on the company's website, with an archived version available for 60 days afterward.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that its CEO, Jack Khattar, will present a company overview and update at two upcoming November conferences. The Stifel 2022 Healthcare Conference is scheduled for November 15, 2022, at 8:00 a.m. ET in New York. The 13th Annual Jefferies London Healthcare Conference will take place on November 17, 2022, at 9:05 a.m. ET / 2:05 p.m. GMT in London. Interested investors can arrange meetings through conference coordinators and access live webcasts on the Company's website.
Supernus Pharmaceuticals reported total revenues of $177.4 million for Q3 2022, a 19% increase year-over-year. The company raised its full-year guidance for operating earnings to $35 million to $45 million and total revenues to $650 million to $680 million. Qelbree prescriptions rose to 94,328, a 50% increase from Q2 2022, with net product sales of $18.3 million. GOCOVRI's sales reached $27.9 million, up 16% from the previous year. Adjusted operating earnings for Q3 were $25.4 million, down from $43.3 million in 2021.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced its upcoming third quarter 2022 financial results, set to be reported after market close on November 8, 2022. CEO Jack Khattar and CFO Tim Dec will host a conference call to discuss the results at 4:30 p.m. ET on the same day.
The call will be available via live webcast on the company's Investor Relations website, where a replay will also be accessible for 60 days following the event.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that the FDA issued a Complete Response Letter (CRL) for its SPN-830 New Drug Application (NDA). This investigational apomorphine infusion device targets motor fluctuations in Parkinson's disease. The CRL requests further information about labeling, product quality, and device performance. Notably, the FDA's initial findings do not ask for additional efficacy and safety studies. Supernus aims to address the FDA's concerns and expedite the NDA resubmission, which will undergo a six-month review timeline.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that President and CEO Jack Khattar will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 8:35 a.m. ET. The conference runs from September 7-9, 2022, at Encore Boston Harbor, Massachusetts. Investors can access a live audio webcast of the presentation via the Company’s website, with an archived replay available for 60 days. Supernus focuses on developing treatments for central nervous system diseases.
Supernus Pharmaceuticals reported Q2 2022 revenues of $170.1 million, reflecting a 20% increase year-over-year. The company's GAAP operating earnings stood at $11.3 million, down from $34.1 million in Q2 2021. Notably, Qelbree prescriptions surged to 62,938, marking a 33% increase from Q1 2022. Net product sales for Qelbree grew by 34% quarter-over-quarter, reaching $11.1 million. The company maintains a robust cash position of $508.2 million.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
